Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunologic aspects of human sarcomas

D J Pritchard, J C Ivins, R E Ritis

    Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer
    |January 1, 1976
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    EXPERIMENTAL MANIPULATION OF ALTERNATIVE PATHWAYS OF DIFFERENTIATION IN CULTURES OF EMBRYONIC CHICK NEURAL RETINA.

    Development, growth & differentiation·2023
    Same author

    Treating hummingbirds as feathered bees: a case of ethological cross-pollination.

    Biology letters·2017
    Same author

    Chondroblastoma.

    Orthopedics·2014
    Same author

    Chordoma of the sacrum.

    Orthopedics·2014
    Same author

    Mayo clinic tumor rounds.

    Orthopedics·2014
    Same author

    Extraabdominal desmoid tumor.

    Orthopedics·2014

    Patients with mesenchymal sarcoma and poor immune responses, including low cytotoxicity, anergy, and reduced lymphocyte transformation, face a worse short-term prognosis. These immune markers can predict clinical outlook in sarcoma patients.

    Area of Science:

    • Immunology
    • Oncology
    • Sarcoma Research

    Context:

    • Mesenchymal sarcoma is a rare cancer.
    • Assessing immune function in cancer patients is crucial for prognosis.

    Purpose:

    • To evaluate the correlation between immune responsiveness and clinical outcomes in mesenchymal sarcoma patients.
    • To identify potential immune biomarkers for predicting short-term prognosis.

    Summary:

    • Forty-seven mesenchymal sarcoma patients underwent immunologic testing, including humoral cytotoxicity, delayed-type hypersensitivity skin tests, and lymphocyte transformation assays.
    • Results indicated that patients exhibiting low humoral cytotoxic indices, anergic skin test responses, or diminished lymphocyte transformation showed a poorer short-term clinical outlook.

    Related Experiment Videos

    Impact:

    • This study highlights the prognostic value of immune status in mesenchymal sarcoma.
    • Findings suggest that immune responsiveness could be a key factor in predicting patient outcomes.